Dynamics of SARS-CoV-2 Variants of Concern in Vaccination Model City in the State of Sao Paulo, Brazil.

Autor: Slavov SN; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., de La-Roque DGL; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., da Costa PNM; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., Rodrigues ES; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., Santos EV; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Borges JS; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., Evaristo M; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., de Matos Maçonetto J; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., Marques AA; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., Milhomens J; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., Rós FA; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., Fonseca V; Pan-American Health Organization/World Health Organization, Lote 19-Avenida das Nações, SEN-Asa Norte, Brasília 70312-970, Brazil., Lima ARJ; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Ribeiro G; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Lima LPO; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Garibaldi PMM; Serrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil., Ferreira NN; Serrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil., Moraes GR; Health Department, Tancredo Almeida Neves Street, 176, Serrana 14150-000, Brazil., Marqueze EC; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Barros CRDS; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Martins AJ; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Coutinho LL; College of Agriculture 'Luiz de Queiroz', University of São Paulo, Pádua Dias Street, 235, Piracicaba 13418-900, Brazil., Calado RT; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil., Borges M; Serrana State Hospital, Ribeirão Preto Medical School, University of São Paulo, Nossa Senhora das Dores Street, 811, Serrana 14150-000, Brazil., Elias MC; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Sampaio SC; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Giovanetti M; Oswaldo Cruz Foundation, Rio de Janeiro 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil.; Department of Science and Technology for Humans and the Environment, University of Campus Bio-Medico di Roma, 00128 Rome, Italy., Alcantara LCJ; Oswaldo Cruz Foundation, Rio de Janeiro 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil., Covas DT; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.; Butantan Institute, Vital Brasil Avenue, 1500, São Paulo 05503-900, Brazil., Kashima S; Center for Cell-based Therapy (CTC), Blood Center of Ribeirão Preto, Tenente Catão Roxo Street, 2 501, Ribeirão Preto 14051-060, Brazil.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2022 Sep 29; Vol. 14 (10). Date of Electronic Publication: 2022 Sep 29.
DOI: 10.3390/v14102148
Abstrakt: From a country with one of the highest SARS-CoV-2 morbidity and mortality rates, Brazil has implemented one of the most successful vaccination programs. Brazil's first model city vaccination program was performed by the CoronaVac vaccine (Sinovac Biotech) in the town of Serrana, São Paulo State. To evaluate the vaccination effect on the SARS-CoV-2 molecular dynamics and clinical outcomes, we performed SARS-CoV-2 molecular surveillance on 4375 complete genomes obtained between June 2020 and April 2022 in this location. This study included the period between the initial SARS-CoV-2 introduction and during the vaccination process. We observed that the SARS-CoV-2 substitution dynamics in Serrana followed the viral molecular epidemiology in Brazil, including the initial identification of the ancestral lineages (B.1.1.28 and B.1.1.33) and epidemic waves of variants of concern (VOC) including the Gamma, Delta, and, more recently, Omicron. Most probably, as a result of the immunization campaign, the mortality during the Gamma and Delta VOC was significantly reduced compared to the rest of Brazil, which was also related to lower morbidity. Our phylogenetic analysis revealed the evolutionary history of the SARS-CoV-2 in this location and showed that multiple introduction events have occurred over time. The evaluation of the COVID-19 clinical outcome revealed that most cases were mild (88.9%, 98.1%, 99.1% to Gamma, Delta, and Omicron, respectively) regardless of the infecting VOC. In conclusion, we observed that vaccination was responsible for reducing the death toll rate and related COVID-19 morbidity, especially during the gamma and Delta VOC; however, it does not prevent the rapid substitution rate and morbidity of the Omicron VOC.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje